{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:50:20Z","timestamp":1785858620613,"version":"3.56.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1097\/01.md.0000178976.62537.6b","type":"journal-article","created":{"date-parts":[[2005,9,13]],"date-time":"2005-09-13T04:57:27Z","timestamp":1126587447000},"page":"261-268","source":"Crossref","is-referenced-by-count":101,"title":["The Relationship of Vascular Glycolipid Storage to Clinical Manifestations of Fabry Disease"],"prefix":"10.1097","volume":"84","author":[{"given":"Surya","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Ries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Kotsopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Schiffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210226","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1034\/j.1399-0004.2001.600107.x","article-title":"Identification of fifteen novel mutations and genotype-phenotype relationship in Fabry disease.","volume":"60","author":"Altarescu","year":"2001","journal-title":"Clin Genet"},{"key":"R2-1-20210226","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/(SICI)1096-8628(19990611)84:5<420::AID-AJMG6>3.0.CO;2-Z","article-title":"Fabry disease: comparison of enzymatic, linkage, and mutation analysis for carrier detection in a family with a novel mutation (30delG).","volume":"84","author":"Ashton-Prolla","year":"1999","journal-title":"Am J Med Genet"},{"key":"R3-1-20210226","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1001\/jama.284.21.2771","article-title":"Clinical features of and recent advances in therapy for Fabry disease.","volume":"284","author":"Brady","year":"2000","journal-title":"JAMA"},{"key":"R4-1-20210226","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course.","volume":"81","author":"Branton","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"R5-1-20210226","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1212\/WNL.32.10.1139","article-title":"Fabry disease: detection of heterozygotes by examination of glycolipids in urinary sediment.","volume":"32","author":"Cable","year":"1982","journal-title":"Neurology"},{"key":"R6-1-20210226","first-page":"67","article-title":"Angiokeratoma corporis diffusum-Fabry's disease.","volume":"34","author":"Colombi","year":"1967","journal-title":"Helv Med Acta"},{"key":"R8-1-20210226","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease.","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"R9-1-20210226","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000060194","article-title":"A new phenotype of Fabry disease with intermediate severity between the classical form and the cardiac variant.","volume":"136","author":"Germain","year":"2001","journal-title":"Contrib Nephrol"},{"key":"R10-1-20210226","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000060188","article-title":"Heterozygotes with Fabry's disease.","volume":"136","author":"Grunfeld","year":"2001","journal-title":"Contrib Nephrol"},{"key":"R11-1-20210226","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1136\/jmg.40.4.e38","article-title":"Clinical presentation in female patients with Fabry disease.","volume":"40","author":"Guffon","year":"2003","journal-title":"J Med Genet"},{"key":"R12-1-20210226","doi-asserted-by":"crossref","first-page":"9319","DOI":"10.1016\/S0021-9258(19)38851-9","article-title":"Alpha-galactosidase A gene rearrangements causing Fabry disease. Identification of short direct repeats at breakpoints in an Alu-rich gene.","volume":"265","author":"Kornreich","year":"1990","journal-title":"J Biol Chem"},{"key":"R13-1-20210226","first-page":"155A","article-title":"A simplified equation to predict glomerular filtration rate from serum creatinine.","volume":"11","author":"Levey","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"R14-1-20210226","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females.","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"},{"key":"R15-1-20210226","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey.","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"R16-1-20210226","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders.","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"R17-1-20210226","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1136\/bmj.297.6653.872","article-title":"Anderson-Fabry disease.","volume":"297","author":"Morgan","year":"1988","journal-title":"BMJ"},{"key":"R18-1-20210226","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1523-1755.2003.00160.x","article-title":"Fabry disease: detection of undiagnosed hemodialysis patients and identification of a \"renal variant\" phenotype.","volume":"64","author":"Nakao","year":"2003","journal-title":"Kidney Int"},{"key":"R19-1-20210226","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","article-title":"An atypical variant of Fabry's disease in men with left ventricular hypertrophy.","volume":"333","author":"Nakao","year":"1995","journal-title":"N Engl J Med"},{"key":"R20-1-20210226","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jchromb.2004.02.032","article-title":"Globotriaosylceramide isoform profiles in human plasma by liquid chromatography-tandem mass spectrometry.","volume":"805","author":"Nelson","year":"2004","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R21-1-20210226","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00431-003-1299-3","article-title":"The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents.","volume":"162","author":"Ries","year":"2003","journal-title":"Eur J Pediatr"},{"key":"R22-1-20210226","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"3rd, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO. Enzyme replacement therapy in Fabry disease: a randomized controlled trial.","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"R23-1-20210226","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/humu.10212","article-title":"Human Gene Mutation Database (HGMD): 2003 update.","volume":"21","author":"Stenson","year":"2003","journal-title":"Hum Mutat"},{"key":"R24-1-20210226","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1523-1755.2002.00097.x","article-title":"Patients with Fabry disease on dialysis in the United States.","volume":"61","author":"Thadhani","year":"2002","journal-title":"Kidney Int"},{"key":"R25-1-20210226","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/j.0022-202X.2004.22425.x","article-title":"Monitoring the 3-year efficacy of enzyme replacement therapy in Fabry disease by repeated skin biopsies.","volume":"122","author":"Thurberg","year":"2004","journal-title":"J Invest Dermatol"},{"key":"R26-1-20210226","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0022-2275(20)41686-4","article-title":"Quantitative analysis of plasma neutral glycosphingolipids by high performance liquid chromatography of their perbenzoyl derivatives.","volume":"18","author":"Ullman","year":"1977","journal-title":"J Lipid Res"},{"key":"R27-1-20210226","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1159\/000169023","article-title":"Novel frameshift mutation in a heterozygous woman with Fabry disease and end-stage renal failure.","volume":"16","author":"Van Loo","year":"1996","journal-title":"Am J Nephrol"},{"key":"R28-1-20210226","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000060195","article-title":"Neurological manifestation of Fabry disease in females.","volume":"136","author":"Wendrich","year":"2001","journal-title":"Contrib Nephrol"},{"key":"R29-1-20210226","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1023\/A:1012993305223","article-title":"Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes.","volume":"24","author":"Whybra","year":"2001","journal-title":"J Inherit Metab Dis"},{"key":"R30-1-20210226","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000060196","article-title":"Clinical manifestation in female Fabry disease patients.","volume":"136","author":"Whybra","year":"2001","journal-title":"Contrib Nephrol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.md.0000178976.62537.6b","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:56:41Z","timestamp":1785855401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005792-200509000-00001"}},"subtitle":["A Cross-Sectional Study of a Large Cohort of Clinically Affected Heterozygous Women"],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1097\/01.md.0000178976.62537.6b","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}